GlucoModicum Makes Headway with Groundbreaking CGM Technology
GlucoModicum, a pioneering health technology company, has reported significant breakthroughs in its development of a needle-free continuous glucose monitor (CGM). This innovative device aims to enhance glucose monitoring for individuals with diabetes, moving the company closer to commercial launch.
Revolutionary Clinical Performance Study
The company recently concluded a comprehensive Clinical Performance Study (CPS), which included an impressive 646 participant visits. This substantial study assessed the device's performance in both Type 2 diabetic patients and healthy volunteers, showcasing GlucoModicum's commitment to thorough research and ethical practices in healthcare technology.
Magnetohydrodynamic Technology Achieves Impressive Accuracy
Utilizing magnetohydrodynamic (MHD) technology, GlucoModicum achieved a Mean Absolute Relative Difference (MARD) of 11.5%. This level of accuracy is nearing the industry benchmark of 10%, highlighting the potential of their system to genuinely compete with existing needle-based CGM systems. The sensors used in the study were produced via the company's proprietary mass-manufacturing techniques, ensuring scalability and reliability in production.
Moving Through Regulatory Milestones
As GlucoModicum prepares for its next phase, it has successfully navigated key regulatory hurdles. Early in 2025, the company completed an ISO 13485 audit with Eurofins Electric & Electronics Finland without any discrepancies, laying a solid groundwork for CE marking—a crucial step before commercial release.
Final Stages Before Market Launch
Subsequently, in the second quarter of the same year, the Finnish medicines agency authorized GlucoModicum to commence a new clinical investigation. This authorization is pertinent for collecting clinical data needed to verify the safety and efficacy of their device prior to the anticipated market entry.
Importance of MARD in Device Evaluation
For context, the MARD statistic is a benchmark used in evaluating glucose monitoring devices, measuring the average difference between device readings and reference values. A lower MARD indicates better accuracy, which is vital for the management of glucose levels in diabetic patients. A MARD of 10% is considered excellent, and GlucoModicum’s technology aims to not only meet but potentially surpass this standard.
CEO Comments on Future Prospects
CEO Jokke Mäki enthusiastically remarked on GlucoModicum's progress, stating, "We have tackled the technical and production challenges that have hampered the industry for years, all while maintaining cost efficiency, placing us in a leading position in the market for needle-free CGMs." With advancements placing them at Technology Readiness Level (TRL) 8, they are poised for commercial launch, a significant leap from earlier developmental stages.
About GlucoModicum
GlucoModicum Ltd is based in Finland and stands at the forefront of health tech innovation, specializing in needle-free health monitoring solutions. Through cutting-edge sensor technologies, they aim to transform diabetes care, making glucose monitoring more accessible and affordable for both patients and healthcare providers.
Company Vision
The vision at GlucoModicum is empowering over a billion people to lead healthier lives through their groundbreaking technologies and commitment to enhancing diabetes management.
Frequently Asked Questions
What is GlucoModicum's main product?
GlucoModicum specializes in developing a needle-free continuous glucose monitor, aimed at improving glucose monitoring for diabetes management.
What makes GlucoModicum's CGM technology unique?
The company utilizes innovative magnetohydrodynamic technology which has achieved an MARD of 11.5%, bringing it close to the industry standard while being needle-free.
What regulatory milestones has GlucoModicum achieved?
GlucoModicum has completed an ISO 13485 audit and received authorization for new clinical investigations from Finland’s medicines agency, paving the way for CE marking.
Why is MARD important in glucose monitoring?
MARD measures the accuracy of glucose monitoring devices by evaluating the difference between device readings and reference values, critical for diabetes management.
What is the company's vision for the future?
GlucoModicum aims to empower over one billion individuals to live healthier lives through enhanced diabetes care and innovative health monitoring solutions.
